Advantages of early biologic therapy and oral peptide as a beacon of hope

The question of whether early biologics treatment can have a lasting effect on the course of psoriasis is the focus of numerous research projects. The GUIDE study investigated the corresponding effects of guselkumab therapy and came up with some interesting findings. Memory T cells appear to play a key role in the long-term modification of the course of the disease. In addition to subcutaneously applied biologics, which are currently considered the gold standard of systemic treatment for psoriasis, promising data is now also available on the orally applied peptide Icotrokinra.